Stockscreener 앱 받기
23.20
5.69%
-1.40
시간 외 거래:
23.20
전일 마감가:
$24.60
열려 있는:
$23.832
하루 거래량:
1,909
Relative Volume:
0.44
시가총액:
$2.16B
수익:
$136.33M
순이익/손실:
$-56.34M
주가수익비율:
-30.92
EPS:
-0.7504
순현금흐름:
$-18.87M
1주 성능:
-4.09%
1개월 성능:
-18.25%
6개월 성능:
-42.29%
1년 성능:
+29.97%
1일 변동 폭
$23.20
$23.99
1주일 범위
$23.20
$24.60
52주 변동 폭
$17.09
$48.45
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
Compare AAPG vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
23.20 | 2.29B | 136.33M | -56.34M | -18.87M | -0.7504 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-12-04 | 개시 | Oppenheimer | Outperform |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-10 | 개시 | BTIG Research | Buy |
| 2025-11-05 | 개시 | Piper Sandler | Overweight |
| 2025-03-27 | 개시 | JP Morgan | Overweight |
모두보기
Ascentage Pharma Group International Adr 주식(AAPG)의 최신 뉴스
Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target - Finviz
Ascentage Pharma to Present at Guggenheim Biotech Summit as Late-Stage Oncology Pipeline Expands - TipRanks
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Ascentage Pharma Wins China IND Clearance for Next-Gen BTK Degrader APG-3288 - TipRanks
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - GlobeNewswire Inc.
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - Sahm
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpTime to Buy? - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Significant Increase in Short Interest - Defense World
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownWhat's Next? - MarketBeat
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update - Defense World
Ascentage Pharma Details 2026 Global Innovation Strategy at J.P. Morgan Healthcare Conference - TipRanks
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial - TipRanks
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 - Sahm
Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives $48.50 Average Price Target from Brokerages - Defense World
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 5.5%Should You Sell? - MarketBeat
Ascentage Pharma to Present at J.P. Morgan Healthcare Conference - TipRanks
Ascentage Pharma to Engage Investors at December 2025 Conferences - MSN
Ascentage Pharma Showcases Promising Data for Olverembatinib at ASH 2025 - The Globe and Mail
Ascentage Pharma showcases promising data for olverembatinib at ASH 2025 - MSN
Ascentage Pharma Unveils Promising Lisaftoclax Data at ASH 2025 - TipRanks
Cash per share of Ascentage Pharma Group International Unsponsored ADR – LSX:A40ZYR - TradingView
ETFs Investing in Ascentage Pharma Group International Unsponsored ADR Stocks - TradingView — Track All Markets
Cash per share of Ascentage Pharma Group International Unsponsored ADR – LS:A40ZYR - TradingView
Ascentage Pharma to Highlight Key Data from ASH 2025 in Upcoming Webcast - TipRanks
Ascentage Pharma Announces New RSU and Share Option Grants - TipRanks
Analysts’ Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD) - The Globe and Mail
Ascentage Pharma’s Olverembatinib Shows Promise in Rare GIST Treatment - TipRanks
Ascentage Pharma Group International (NASDAQ:AAPG) Now Covered by Analysts at Truist Financial - Defense World
Ascentage Pharma Group International Adr (AAPG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):